![]() |
6th ESACP Congress, Heidelberg, April 7-11, 1999 |
A064
Given the demography of current and ex-smoking populations in North America,
lung cancer will be a major problem in the forseeable future. Early
detection and treatment of lung cancer holds great promise for the management
of this disease. A number of chemo-prevention studies are being conducted
in our laboratories to investigate the protective effect of agents such as
retinol. One method of monitoring chemo-preventive agents is through
histological evaluation. However intra-and inter-observer variability
introduces significant error. We investigated quantitative analysis of more
than 1500 pre-inavsive neoplastic bronchial biopsies. Using an interactive
version of the Cyto-savant (Oncometric Imaging Corp.) cytometric and tissue
architectural data were collected from these biopsies. The Loss of
Heterozygosity (LOH) at ten sites commonly associated with cancer was
analyzed and a LOH index was calculated for ~400 biopsies. Using data from
the normal and cancer groups in one hand, and data from biopsies without LOH
and biopsies with high Frequency of Regional Loss (FRL) in an other hand,
quantitative morphometric and architectural indices were generated and
calculated for all collected biopsies. These quantitative indices will be
compared and correlated with the pathology grade and the FRL index. Potential
use of image cytometry as intermediate endpoint biomarker for lung cancer
chemoprevention will be discussed.
CORRELATION OF PATHOLOGY, LOSS OF HETEROZYGOTY, MORPHOMETRY AND ARCHITECTURE
INDICES IN BRONCHIAL DYSPLASTIC LESIONS
Guillaud M 1, Lam S 1, Klein-Parker H 1, Gazdar A 2,
Payne P 1, Leriche J 3, Dawe Ch 1, Korbelic J 1,
Palcic B 1, Macaulay CE 1
1) Cancer Imaging Department, British Columbia Cancer Agency, Vancouver,
Canada,
2) University of Texas, Southewestern Medical Center, Dallas, Texas, USA
3) Department of Pathology and Laboratory Medicine, British Columbia Cancer
Agency, Canada